{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:29:48Z","timestamp":1786663788969,"version":"build-2736575974"},"reference-count":76,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001791","name":"Griffith University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001791","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010230","name":"Queensland Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001794","name":"University of Queensland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000927","name":"Prostate Cancer Foundation of Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000927","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1116334"],"award-info":[{"award-number":["1116334"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["gimjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genetics in Medicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.gim.2025.101463","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:14:57Z","timestamp":1747912497000},"page":"101463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The cost-utility of targeted germline BRCA testing in localized prostate cancer followed by cascade testing first-degree relatives with pathogenic variants"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-840X","authenticated-orcid":false,"given":"Srinivas","family":"Teppala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Scuffham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Edmunds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham","family":"Tuffaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gim.2025.101463_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"14","key":"10.1016\/j.gim.2025.101463_bib5","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","article-title":"Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer","volume":"31","author":"Castro","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gim.2025.101463_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"issue":"22","key":"10.1016\/j.gim.2025.101463_bib7","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gim.2025.101463_bib8","article-title":"PARP inhibition in prostate cancer with homologous recombination repair alterations","volume":"5","author":"von Werdt","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"13","key":"10.1016\/j.gim.2025.101463_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.2217\/pgs-2021-0061","article-title":"Is olaparib cost effective in metastatic castration-resistant prostate cancer patients with at least one favorable gene mutation in BRCA1, BRCA2 or ATM?","volume":"22","author":"Li","year":"2021","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gim.2025.101463_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.610601","article-title":"Cost-effectiveness of genomic test-directed olaparib for metastatic castration-resistant prostate cancer","volume":"11","author":"Su","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib12","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1017\/S0266462324000011","article-title":"The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer","volume":"40","author":"Teppala","year":"2024","journal-title":"Int J Technol Assess Health Care"},{"issue":"15","key":"10.1016\/j.gim.2025.101463_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.21037\/atm-22-3637","article-title":"Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States","volume":"10","author":"Xu","year":"2022","journal-title":"Ann Transl Med"},{"issue":"11","key":"10.1016\/j.gim.2025.101463_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.jval.2024.06.019","article-title":"The cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers","volume":"27","author":"Teppala","year":"2024","journal-title":"Value Health"},{"issue":"32","key":"10.1016\/j.gim.2025.101463_bib15","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"issue":"10398","key":"10.1016\/j.gim.2025.101463_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41391-023-00676-0","article-title":"Guidelines for genetic testing in prostate cancer: a scoping review","volume":"27","author":"Tuffaha","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib18","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/cancers14041004","article-title":"Clinical management of prostate cancer in high-risk genetic mutation carriers","volume":"14","author":"Clark","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.gim.2025.101463_bib19","first-page":"645","article-title":"Germline testing in prostate cancer: when and who to test","volume":"35","author":"Sokolova","year":"2021","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.gim.2025.101463_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221143884","article-title":"Delivering genetic testing for patients with prostate cancer: moving beyond provider knowledge as a barrier to care","volume":"30","author":"Gunn","year":"2023","journal-title":"Cancer Control"},{"issue":"22","key":"10.1016\/j.gim.2025.101463_bib22","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.2217\/fon-2021-0153","article-title":"Real-world genetic testing patterns in metastatic castration-resistant prostate cancer","volume":"17","author":"Shore","year":"2021","journal-title":"Future Oncol"},{"issue":"18","key":"10.1016\/j.gim.2025.101463_bib23","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib24","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1186\/s12885-020-07174-9","article-title":"South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC). Survival outcomes in men with a positive family history of prostate cancer: a registry based study","volume":"20","author":"Ang","year":"2020","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2014.30","article-title":"Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease","volume":"110","author":"Leongamornlert","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.gim.2025.101463_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.gim.2025.101463_bib27","author":"Qu"},{"key":"10.1016\/j.gim.2025.101463_bib28","author":"Hayes"},{"key":"10.1016\/j.gim.2025.101463_bib29","author":"Graham"},{"issue":"15","key":"10.1016\/j.gim.2025.101463_bib32","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","article-title":"Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation","volume":"32","author":"Finch","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.gim.2025.101463_bib33","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-15-1465","article-title":"Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review","volume":"22","author":"Li","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.gim.2025.101463_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/gim.2017.231","article-title":"Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers","volume":"20","author":"Tuffaha","year":"2018","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.gim.2025.101463_bib35","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1200\/JCO.2009.22.7991","article-title":"Survival analysis of cancer risk reduction strategies for BRCA1\/2 mutation carriers","volume":"28","author":"Kurian","year":"2010","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00006534-200009020-00001","article-title":"Breast Cancer following Breast Reduction Surgery in Sweden","volume":"106","author":"Boice","year":"2000","journal-title":"Plast Reconstr Surg"},{"issue":"2","key":"10.1016\/j.gim.2025.101463_bib37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.gim.2025.101463_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","article-title":"Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the Impact study","volume":"66","author":"Bancroft","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.eururo.2021.09.029","article-title":"Association of inherited mutations in DNA repair genes with localized prostate cancer","volume":"81","author":"Lee","year":"2022","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","article-title":"Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study","volume":"77","author":"Nyberg","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib41","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/JU.0000000000000713","article-title":"Long-term outcomes of active surveillance for prostate cancer: the Memorial Sloan Kettering Cancer Center experience","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib42","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/JU.0000000000000742","article-title":"Risk of metastasis in men with grade Group 2 prostate cancer managed with active surveillance at a tertiary Cancer Center","volume":"203","author":"Carlsson","year":"2020","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib43","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/JU.0000000000001313","article-title":"The long-term risks of metastases in men on active surveillance for early stage prostate cancer","volume":"204","author":"Maggi","year":"2020","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.gim.2025.101463_bib44","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.gim.2025.101463_bib46","doi-asserted-by":"crossref","first-page":"680","DOI":"10.5694\/mja13.10848","article-title":"Preventing breast and ovarian cancers in high-risk BRCA1 and BRCA2 mutation carriers","volume":"199","author":"Collins","year":"2013","journal-title":"Med J Aust"},{"issue":"8","key":"10.1016\/j.gim.2025.101463_bib47","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s11136-014-0676-x","article-title":"A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA","volume":"23","author":"Clemens","year":"2014","journal-title":"Qual Life Res"},{"issue":"12","key":"10.1016\/j.gim.2025.101463_bib48","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jval.2021.06.001","article-title":"Cost-effectiveness of magnetic resonance imaging in prostate cancer screening: a microsimulation study","volume":"24","author":"Hao","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older","volume":"43","author":"Stewart","year":"2005","journal-title":"Med Care"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.euo.2019.01.004","article-title":"A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer","volume":"2","author":"Sathianathen","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.gim.2025.101463_bib51","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S1470-2045(20)30449-6","article-title":"Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study","volume":"21","author":"Fizazi","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.gim.2025.101463_bib52","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1080\/13696998.2019.1661581","article-title":"Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance","volume":"22","author":"Barqawi","year":"2019","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib53","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/jnci\/dju380","article-title":"Cost-effectiveness of population screening for BRCA mutations in Ashkenazi Jewish women compared with family history-based testing","volume":"107","author":"Manchanda","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.gim.2025.101463_bib54","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/erp.10.65","article-title":"Health-state utility values in breast cancer","volume":"10","author":"Peasgood","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the G\u00f6teborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib58","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the Impact study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.gim.2025.101463_bib59","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/ajco.12582","article-title":"Long-term health care costs for patients with prostate cancer: a population-wide longitudinal study in New South Wales, Australia","volume":"13","author":"Cronin","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"9","key":"10.1016\/j.gim.2025.101463_bib60","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32900","article-title":"Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy","volume":"6","author":"Falagario","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"20","key":"10.1016\/j.gim.2025.101463_bib61","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1002\/cncr.34916","article-title":"Outcomes after definitive radiation therapy for localized prostate cancer in a national health care delivery system","volume":"129","author":"Herr","year":"2023","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.gim.2025.101463_bib62","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1200\/JCO.2009.22.2265","article-title":"Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix","volume":"28","author":"Zelefsky","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.gim.2025.101463_bib63","doi-asserted-by":"crossref","first-page":"e1042","DOI":"10.1634\/theoncologist.2019-0495","article-title":"Prognostic value of germline DNA repair gene mutations in de novo metastatic and castration-sensitive prostate cancer","volume":"25","author":"Wei","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib64","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.18.00358","article-title":"PROREPAIR-B: a prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.gim.2025.101463_bib65","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","article-title":"Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors","volume":"38","author":"Shore","year":"2021","journal-title":"Adv Ther"},{"issue":"9","key":"10.1016\/j.gim.2025.101463_bib66","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s10147-021-01956-2","article-title":"Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents","volume":"26","author":"Miyake","year":"2021","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib68","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrclinonc.2014.68","article-title":"High-risk prostate cancer-classification and therapy","volume":"11","author":"Chang","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.gim.2025.101463_bib98","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jval.2015.08.012","article-title":"Health-related quality of life and health utilities in metastatic castrate-resistant prostate cancer: A survey capturing experiences from a diverse sample of UK patients","volume":"18","author":"Lloyd","year":"2015","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.gim.2025.101463_bib102","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/IGC.0b013e3181dbd13f","article-title":"Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years","volume":"20","author":"Gordon","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1016\/j.gim.2025.101463_bib103","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/cancers10120477","article-title":"Screening BRCA1 and BRCA2 mutation carriers for breast cancer","volume":"10","author":"Warner","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.gim.2025.101463_bib105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.adro.2017.12.001","article-title":"Superior metastasis-free survival for patients with high-risk prostate cancer treated with definitive radiation therapy compared to radical prostatectomy: a propensity score-matched analysis","volume":"3","author":"Markovina","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib106","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/21681805.2022.2108140","article-title":"Biochemical recurrence after radical prostatectomy \u2013 a large, comprehensive, population-based study with long follow-up","volume":"56","author":"Ax\u00e9n","year":"2022","journal-title":"Scand J Urol"},{"issue":"2","key":"10.1016\/j.gim.2025.101463_bib109","doi-asserted-by":"crossref","first-page":"76","DOI":"10.18773\/austprescr.2017.014","article-title":"Economic evaluation of medicines","volume":"40","author":"Taylor","year":"2017","journal-title":"Aust Prescr"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-98737-8","article-title":"Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design","volume":"11","author":"Blomen","year":"2021","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gim.2025.101463_bib112","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.euf.2021.04.018","article-title":"A clinical trial of prophylactic prostatectomy for BRCA2 mutation carriers: is now the time?","volume":"7","author":"Clark","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib113","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1457496919883962","article-title":"Prostatectomy versus observation for localized prostate cancer: a meta-analysis","volume":"110","author":"Luo","year":"2021","journal-title":"Scand J Surg"},{"issue":"10","key":"10.1016\/j.gim.2025.101463_bib114","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.gim.2025.101463_bib115","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10198-011-0326-y","article-title":"The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications","volume":"13","author":"Rodr\u00edguez Barrios","year":"2012","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib116","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","article-title":"A review of the cost-effectiveness of genetic testing for germline variants in familial cancer","volume":"26","author":"Teppala","year":"2023","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.gim.2025.101463_bib117","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jval.2020.09.016","article-title":"Cost-effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review","volume":"24","author":"Koldehoff","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.gim.2025.101463_bib118","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.clinthera.2016.03.009","article-title":"Using patient-reported outcomes to compare relative burden of cancer: EQ-5D and functional assessment of cancer therapy-general in eleven types of cancer","volume":"38","author":"Pickard","year":"2016","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.gim.2025.101463_bib119","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/00019053-200725050-00002","article-title":"Health utilities using the EQ-5D in studies of cancer","volume":"25","author":"Pickard","year":"2007","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"10.1016\/j.gim.2025.101463_bib120","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.jval.2023.05.016","article-title":"Does EQ-5D tell the whole story? Statistical methods for comparing the thematic coverage of clinical and generic outcome measures, with application to breast cancer","volume":"26","author":"Hern\u00e1ndez","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.gim.2025.101463_bib121","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/cancers14010147","article-title":"Assessment of health-related quality of life in patients with advanced prostate cancer-current state and future perspectives","volume":"14","author":"Kretschmer","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"20","key":"10.1016\/j.gim.2025.101463_bib122","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.2003.10.100","article-title":"Long-term psychological impact of carrying a BRCA1\/2 mutation and prophylactic surgery: a 5-year follow-up study","volume":"21","author":"van Oostrom","year":"2003","journal-title":"J Clin Oncol"}],"container-title":["Genetics in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098360025001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:25:02Z","timestamp":1786663502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098360025001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":76,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1098360025001108"],"URL":"https:\/\/doi.org\/10.1016\/j.gim.2025.101463","relation":{},"ISSN":["1098-3600"],"issn-type":[{"value":"1098-3600","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-utility of targeted germline BRCA testing in localized prostate cancer followed by cascade testing first-degree relatives with pathogenic variants","name":"articletitle","label":"Article Title"},{"value":"Genetics in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gim.2025.101463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American College of Medical Genetics and Genomics. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101463"}}